Q-omics provides the consensus-scored MT-ND6 profile across patient tissues and cancer cell-line models. MT-ND6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT-ND6 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MT-ND6 RNA expression shows 17,761 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MT-ND6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-ND6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-ND6 survival associations across molecular data types. MT-ND6 RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-ND6 RNA expression–survival associations across cancer types. High MT-ND6 expression shows unfavorable associations in DLBC, but favorable associations in ACC, LGG, KIRC, LIHC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for MT-ND6 RNA expression.
This table summarizes MT-ND6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT-ND6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-ND6 shows lower tumor expression in HNSC, LUAD, BRCA, COAD, LUSC and UCEC. The HNSC box plot shows higher MT-ND6 RNA expression in normal versus tumor tissue (log2 FC = −1.800, t-test p < 0.001).
This table shows molecular features associated with MT-ND6 in patient tissues and cancer cell lines. In patient samples, MT-ND6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-ND6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
